newsfilter
← Latest News
GlobeNewswire·

Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026

RMD
  • ResMed reported Q1 fiscal 2026 revenue of $1.34 billion, a 9% year-over-year increase and an 8% increase on a constant currency basis.
  • Gross margin rose 290 basis points to 61.5%, while non-GAAP gross margin increased 280 basis points to 62.0%.
  • Income from operations grew 15% to $446.5 million, with non-GAAP income from operations up 19% to $482.1 million.
  • Diluted earnings per share were $2.37, while non-GAAP diluted earnings per share reached $2.55, representing a 16% non-GAAP increase.
  • Operating cash flow for the quarter totaled $457 million.
  • Revenue in the U.S., Canada, and Latin America grew 10%, while Europe, Asia, and other markets grew 6% on a constant currency basis.
  • The company recorded $16 million in restructuring charges related to workforce planning aligned with 2030 strategic priorities.
  • Selling, general, and administrative expenses increased 7% on a constant currency basis due to VirtuOx acquisition costs, employee costs, and marketing investments.
  • The board declared a quarterly cash dividend of $0.60 per share with a record date of November 13, 2025, and payment date of December 18, 2025.
  • During the quarter, ResMed repurchased 523,000 shares for $150 million and paid $88 million in dividends.
  • The company announced a landmark study projecting 77 million U.S. adults with OSA by 2050 and received dual Red Dot Product Design 2025 awards.
  • Nicole Mowad-Nassar was elected to the board, while Rich Sulpizio announced his upcoming retirement.
  • Cash and cash equivalents increased to $1.38 billion at the end of the quarter.
  • A webcast of the earnings conference call is scheduled for 1:30 p.m. U.S. Pacific Time on October 30, 2025.